Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
03 Feb 2024
03 Feb 2024
Historique:
received:
27
06
2023
accepted:
19
12
2023
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
3
2
2024
Statut:
aheadofprint
Résumé
Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real-life data remain scarce. BrIDGE was an observational, prospective, single-cohort, multicentre study that recruited patients with moderate-to severe plaque psoriasis in Greece. The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12-16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab. Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, 'worst case' and 'best case' scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables. Based on the 'as observed data', 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12-16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12-16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%. Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.
Sections du résumé
BACKGROUND
BACKGROUND
Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real-life data remain scarce. BrIDGE was an observational, prospective, single-cohort, multicentre study that recruited patients with moderate-to severe plaque psoriasis in Greece.
OBJECTIVES
OBJECTIVE
The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12-16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.
METHODS
METHODS
Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, 'worst case' and 'best case' scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.
RESULTS
RESULTS
Based on the 'as observed data', 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12-16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12-16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.
CONCLUSIONS
CONCLUSIONS
Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : LEO Pharma
Informations de copyright
© 2024 European Academy of Dermatology and Venereology.
Références
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301-1315.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983-994.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945-1960.
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073-1113.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.
Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15:1185-1194.
European Medicines Agency. Brodalumab. Available from: https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf
Farahnik B, Beroukhim K, Abrouk M, Nakamura M, Zhu TH, Singh R, et al. Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6:111-124.
Galluzzo M, Caldarola G, De Simone C, Bernardini N, Moretta G, Pallotta S, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21:1299-1310.
Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, et al. BRILLIANT working group. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35:693-700.
Tampouratzi E, Papakonstantis M, Katsantonis J, Sidiropoulos T, Delli F, Efthymiadis K, et al. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of four tertiary hospitals. Dermatol Ther. 2022;35:e15532.
Rompoti N, Politou M, Stefanaki I, Vavouli C, Papoutsaki M, Neofotistou A, et al. Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks. J Eur Acad Dermatol Venereol. 2023;37:689-697.
Papadavid E, Zafeiriou E, Georgiou S, Roussaki-Schulze AV, Spiliopoulos T, Vryzaki E, et al. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece. J Dermatolog Treat. 2022;33:3053-3059.
Galan-Gutierrez M, Font-Ugalde P, Padilla L, Hernandez-Montoya C, Godoy D, Armario-Hita JC, et al. Brodalumab: efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain. Int J Dermatol. 2023;62:700-706.
Imafuku S, Ohata C, Okubo Y, Tobita R, Saeki H, Mabuchi T, et al. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study. J Dermatol Sci. 2022;105:176-184.
Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, et al. Early development and qualitative evidence of content validity for the psoriasis symptom inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013;24:255-260.
Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med Etika Bioet. 2001;9(1-2):12-19.
Epstein M. International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2005;14:589-595.
ENCePP guide on methodological standards in pharmacoepidemiology. Available from: https://www.encepp.eu. Accessed July 2023.
Rigopoulos D, Angelakopoulos C, Apalla Z, Georgiou S, Delli F, Drosos A, et al. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: results from an interim analysis of the BrIDGE study. Dermatol Ther. 2022;35:e15886.
Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M, Rivera R, Carrascosa JM, et al. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: a multicentre retrospective study in a Spanish population. Australas J Dermatol. 2023;64:e317-e326.
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273-286.
Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo-and active, comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82:352-359.
Papp K, Menter A, Leonardi C, Soung J, Weiss S, Pillai R, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183:1037-1048.
Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2021;35:450-457.
Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320-328.
Yeung J, Vender R, Turchin I, Shukla R, Maari C, Hong CH, et al. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. J Am Acad Dermatol. 2021;84:1169-1171.
Kimmel G, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857-859.
Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K, et al. Successful intra-class switching among IL-17antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421-424.
Kromer C, Wilsmann-Theis D, Gerdes S, Krebs S, Pinter A, Philipp S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study. J Dermatolog Treat. 2021;32:878-882.
Gaudet V, Yap B, Hassan S, Barbeau M. Brodalumab for plaque psoriasis: a Canadian real-world experience at 2-years post-launch. J Cutan Med Surg. 2023;27:226-235.
Edson-Heredia E, Sterling KL, Alatorre CI, Cuyun Carter G, Paczkowski R, Zarotsky V, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134:18-23.